Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Atezolizumab plus sacituzumab govitecan to prevent recurrence in TNBC (ASPRIA)

Phase 2 trial of atezolizumab plus sacituzumab govitecan for six cycles in triple-negative breast cancer. The registry primary outcome is the rate of undetectable circulating tumor cell-free DNA. ClinicalTrials.gov lists the study as recruiting.

Dana-Farber Cancer Institute